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dCase report
A 26-year-old African-American male presented at
the Oral Surgery Outpatient Clinic for evaluation
of an oral lesion. He first noticed a ‘‘gum boil’’ four
months ago which has been steadily increasing in
size since its appearance. He failed to seek medical
attention for this lesion since it was not painful or
has not bled in the past. He also reported unex-
plained weight loss in the last six months and feb-
rile episodes. His previous medical history was
unremarkable. He reported no known drug allergy.
At the time of our examination he was taking amox-
icillin. He denied tobacco use, alcohol use, illicit
drugs use or intravenous drug use.741-9409/$ - see front matter c 2005 Elsevier Ltd. All rights reser
oi:10.1016/j.ooe.2005.08.003
* Tel.: +1 713 500 4210.
E-mail address: orasmile@gmail.comThe patient’s extra oral exam revealed a normo-
cephalic facial symmetry with no signs or symp-
toms of acute infection, swelling or tenderness.
There was a raised well defined reddish nodular
mass measuring 2.0 · 1.8 cm on the posterior side
of his head (Fig. 1). Palpable lymph nodes were
appreciated on his left submandibular and poster-
ior cervical chains; the nodes were firm, mobile
and painless. Poor oral hygiene was noted with
moderate dental plaque and calculus accumulation
and generalized gingival edema. Bleeding on peri-
odontal probing was generalized. There was no
radiographic evidence of bone loss and the deepest
probing was around 4 mm. Additionally, there was
a 2 · 1.8 cm raised, dark red, soft, exophytic
enlargement of the mandibular attached gingiva
of lower right canine on the facial and lingual as-
pect, with a smooth surface, ill defined marginsved.
Figure 1 A raised well defined reddish nodular mass
measuring 2.0 · 1.8 cm on the posterior side of the head.
Figure 2 A raised, dark red, soft, exophytic enlarge-
ment of the mandibular attached gingiva of lower right
canine on the facial aspect, with a smooth surface, and
ill defined margins.
Figure 3 A 2 · 1.8 cm raised, dark red, soft, exophytic
enlargement of the mandibular attached gingiva of lower
right canine on the lingual aspect.
Figure 4 An ill-defined raised, diffuse, reddish, soft,
nodular enlargement on the posterior right hard palate
focal areas of ulceration involving the soft palate and the
uvula and progressing into the oropharynx.
Disseminated oral Kaposi sarcoma lesion with extensive visceral involvement 19and negative blanching (Figs. 2, 3). The lesion was
not tender to palpation and showed no erosions or
ulcerations. Another 5 · 4 cm ill-defined raised,
diffuse, reddish-blue, soft, nodular enlargement
on the posterior right hard palate was observed,
involving the soft palate and the uvula and pro-
gressing into the oropharynx (Fig. 4). This lesion
showed an ulcerated surface and there was no ten-
derness. The patient repeatedly denied any history
of dysphasia or dyspnea or difficulty to chew asso-
ciated with this lesion. There were no other oral le-
sions, tumors or masses noted intraorally.
Two other dark-red nodules were observed on
his left arm and forehead with the same character-
istics described for the oral lesions (Figs. 5, 6). The
patient agreed to undergo an incisional biopsy of
the exophytic tumor on the facial aspect of at-tached gingiva. A local anesthesia infiltration of
the right mental nerve was obtained using 1.8 mL
of lidocaine 2% with epinephrine 1:100,000. The
tumor was excised and placed in 10% formalin
and submitted for histopathological diagnosis.
The histologic examination revealed a cellular
spindle tumor within the connective tissue, numer-
ous extravasated erythrocytes and poorly defined
vascular slits. These microscopic findings plus the
clinical presentation and the medical history were
consistent with a diagnosis of Kaposi’s sarcoma.
Additionally, head and neck magnetic resonance
imaging (MRI) with contrast solution were ordered
for further assessment of respiratory and/or esoph-
ageal tract obstruction and did not show any major
obstruction of upper airways.
Figure 5 A dark-red macule less than 0.5 · 0.5 cm in
diameter on the left forehead.
Figure 6 A dark-red nodule on his left arm.
20 K. ShettyWe discussed the results with patients and the
risk factors for HIV were elucidated. He agreed to
take the enzyme-linked immunosorbent assay
(ELISA) test. The test was positive and his status
as HIV seropositive was confirmed by the western
blot procedure. Subsequent biopsies of the cutane-
ous and pharyngeal lesions were consistent with a
similar diagnosis of AIDS-related Kaposi’s sarcoma.
At the time of his hospital admission his CD4+
lymphocytes count was 4.8 cells/cc3 and his CD8+
lymphocytes count was 57.3 cells/cc3 (CD4/CD8
ratio = 0.1) with a viral load of 35000.Discussion
Kaposi’s sarcoma (KS) is a malignant, multifocal
systemic disease that originates in the vascular
endothelium and has a very variable clinicalcourse. The disease, first described by the Hungar-
ian dermatologist Moritz Kaposi in 1872, was rare
and found classically in elderly men of Italian, Jew-
ish, or Slavic ancestry.1 With the advent of the AIDS
epidemic, KS has become one of the most common
malignancies associated with HIV infection and was
one of the first diseases to define AIDS in 1981.2
KS is traditionally separated into four different
types: classic, which primarily affects elderly
men of Mediterranean and eastern European origin;
endemic, which is common in parts of Africa; epi-
demic or AIDS-associated; and transplantation-
associated. The human herpes virus-8 infection
and its pathogenic process characterize all four
types. Although most Americans remain at low risk
for infection of AIDS-HHV-8 KS, homosexual and
bisexual men are at strikingly high risk as a result
of sexual transmission in some form.3
KS sometimes begins as a single lesion of the oral
mucosa but more frequently begins as multiple le-
sions. Fifty percent of the affected patients show
oral lesions and 20–25% of these lesions may be
the initial site of involvement.4 KS can invade bone
and create tooth mobility when involves the palate
or gingiva. The lesion initially is a flat brown or red-
dish purple macule that does not blanch with pres-
sure. The neoplasm may develop into plaques or
nodules, and this progressive malignancy may
disseminate to lymph nodes and organ systems.
Morbidity of KS oral lesions may be associated
with pain, bleeding, and functional interferences
caused by the tumor.
Months before manifestation of the tumors,
HHV-8 viremia leads to development of specific
antibodies. In most cases, epidemic KS causes
widespread lesions that erupt in many places soon
after AIDS develops. Lesions of epidemic KS may
arise on the skin and the mouth and may affect
the lymph nodes and other organs, usually the gas-
trointestinal tract, lung, liver, and spleen. In con-
trast, classic KS usually involves only one or a few
areas of skin, most often the lower legs.5 At the
time of diagnosis of epidemic KS some people
experience no symptoms, especially if their only le-
sions are on the skin. However, many of those with
epidemic KS – even those with no skin lesions, will
have swollen lymph nodes, unexplained fever, or
weight loss. Eventually, in almost all cases, epi-
demic KS spreads throughout the body. Extensive
KS lung involvement can be fatal. More often, how-
ever, patients die of other AIDS-related complica-
tions, such as infections.6
KS afflicts of 10–20% of HIV-positive patients.
Some studies suggest that HIV-positive patients
with Kaposi’s sarcoma have a shorter survival than
might be predicted from their CD4 concentrations.7
Disseminated oral Kaposi sarcoma lesion with extensive visceral involvement 21The authors reported that patients with lesions of
the oral mucosa had a higher death rate than those
with exclusively cutaneous manifestations of the
disease.
KS treatment has been rapidly improving with
many new options currently under study or recently
proven to be efficacious and licensed for use in pa-
tients with AIDS.8 Various local therapies aim to
eradicate small lesions; however, they do not af-
fect the KS in general nor the likelihood of its
recurrence. Systemic chemotherapy treats exten-
sive visceral involvement, which no other form of
treatment may affect.9,10 Newer treatment ap-
proaches are aimed at HHV-8 or at the inflamma-
tory cytokine or angiogenic milieu necessary for
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